Docetaxel, Capecitabine and Concurrent Radiotherapy for Gastric Cancer Patients with Postoperative Locoregional Recurrence. Issue 4 (July 2015)

• Record Type: Journal Article
• Authors: Xie, Jian; Liang, Ning; Qiao, Lili; Su, Lei; Li, Kai; Luo, Hui; Zhang, Jingxin; Zhang, Jiandong
• Is Part Of: Tumori. Volume 101:Issue 4(2015)
• Page Start: 433
• Page End: 439
• Publication Date: 2015-07
• Subjects: Radiochemotherapy -- Capecitabine -- Docetaxel -- Gastric cancer -- Locoregional recurrence; Cancer -- Periodicals; 616.994
• DOI: 10.5301/tj.5000336
• Languages: English
• ISSNs: 0300-8916

Abstract

Aims and background: This study aimed to assess the efficacy of concurrent chemoradiotherapy (CCRT) with docetaxel and capecitabine versus docetaxel and capecitabine chemotherapy for gastric cancer patients with postoperative locoregional recurrence. Methods: From 2008 to 2011, 81 patients with locoregional recurrence after curative resection of gastric cancer were enrolled. Thirty-nine (CCRT group) received involved-field radiotherapy with oral capecitabine (twice daily, 5 days/week) and intravenous infusion of docetaxel (once weekly). The remaining 42 patients (chemotherapy group) were treated with oral capecitabine (twice daily, days 1-14) followed by intravenous infusion of docetaxel (days 1 and 8). The overall response rate, overall symptom control rate, toxicity or adverse reactions, and overall survival (OS) were compared. Results: The overall response rate (CR+PR) was significantly higher in the CCRT group (79.5%) than the chemotherapy group (54.8%). In CCRT individuals, the control rates for bleeding, pain, and dysphagia/obstruction were 87.5%, 75%, and 71.4%, respectively, versus 63.2%, 50%, and 28.6% in the chemotherapy group. CCRT patients had a better symptom control rate than the chemotherapy group (52.5% vs. 80%). Adverse reactions were non-significantly more severe in CCRT patients. Finally, median OS was longer in the CCRT vs. chemotherapy group (14.2 vs. 6.4 months). Conclusions: Involved-field radiotherapy with docetaxel and capecitabine was effective and well tolerated. These findings provide further insight into the role of CCRT in gastric cancer. However, this was not a randomized controlled study and the number of patients was relatively small, suggesting that cautious interpretation of cumulative estimates is warranted.